Rosiglitazone for type 2 diabetes mellitus

Richter, Bernd; Bandeira‐Echtler, Elizabeth; Bergerhoff, Karla; Clar, Christine; Ebrahim, Susanne H

doi:10.1002/14651858.cd006063.pub2

Cited by 80 publications

(68 citation statements)

References 142 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The systematic review by Richter et al 52 assessed the effects of rosiglitazone in the treatment of type 2 diabetes. The study by Lebovitz et al 53 was identified as including an outcome measure relevant to kidney disease.…”

Section: What Is the Evidence?mentioning

confidence: 99%

“…Blood pressure was not statistically different between groups. The results were considered to be consistent with previous studies that troglitazone but not metformin or glibenclamide reduced urinary albumin excretion rate.The systematic review by Richter et al 52 assessed the effects of rosiglitazone in the treatment of type 2 diabetes. The study by Lebovitz et al 53 was identified as including an outcome measure relevant to kidney disease.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Prevention and management of chronic kidney disease in type 2 diabetes

Chadban¹,

Howell²,

Twigg³

et al. 2010

Nephrology

View full text Add to dashboard Cite

GUIDELINESBlood glucose control should be optimized aiming for a general HbA1c target 27%. (Grade A*). In people with type 2 diabetes and microalbuminuria or macroalbuminuria, angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor ACEi antihypertensives should be used to protect against progression of kidney disease. (Grade A*). The blood pressure (BP) of people with type 2 diabetes should be maintained within the target range. ARB or ACEi should be considered as antihypertensive agents of first choice. Multi-drug therapy should be implemented as required to achieve target blood pressure. (Grade A*) People with type 2 diabetes should be informed that smoking increases the risk of chronic kidney disease (CKD) (Grade B*). Table A1: Definition of NHMRC grades of recommendation. Also refer to NHMRC 'National Evidence Based Guidelines for Diagnosis, Prevention and Management of CKD in Type 2 Diabetes' (see http://www.cari.org.au) for Levels of Evidence and Evidence Grading which were undertaken in accordance with the NHMRC Hierarchy of Evidence procedure. *Refer to SUGGESTIONS FOR CLINICAL CARE• The HbA1c target may need to be individualized taking in to account history of hypoglycaemia and co-morbidities. (refer to NHMRC Evidence Based Guideline for Blood Glucose Control in Type 2 Diabetes at http://www.nhmrc.gov.au).• Systolic blood pressure (SBP) appears to be the best indicator of the risk of CKD in type 2 diabetes. However, an optimum and safest lower limit of SBP has not been clearly defined.• In people with type 2 diabetes antihypertensive therapy with ARB or ACEi decreases the rate of progression of albuminuria, promotes regression to normoalbuminuria, and may reduce the risk of decline in renal function.• Due to potential renoprotective effects, the use of ACEi or ARB should be considered for the small subgroup of people with normal BP who have type 2 diabetes and microalbuminuria.• The extent to which interventions with lipid lowering therapy reduces the development of CKD in people with type 2 diabetes is unclear. As there is limited evidence relating to effects of lipid treatment on the progression of CKD in people with type 2 diabetes, blood lipid profiles should be managed in accordance with guidelines for prevention and management of cardiovascular disease (CVD).• Lifestyle modification (diet and physical activity) is an integral component of diabetes care (refer to the NHMRC Evidence Based Guidelines for Blood Glucose Control in Type 2 Diabetes), however, there are insufficient studies of suitable quality to enable dietary recommendations to be made with respect to prevention and/or management of CKD in people with type 2 diabetes. BACKGROUND Aim of the guidelineThis guideline topic has been taken from the NHMRC 'National Evidence Based Guidelines for Diagnosis, Prevention and Management of CKD in Type 2 Diabetes' which can be found in full at the CARI website (http:// www.cari.org.au). The NHMRC guideline covers issues related to the assessment and prevention of CKD in individu...

show abstract

Section: What Is the Evidence?mentioning

confidence: 99%

mentioning

confidence: 99%

Prevention and management of chronic kidney disease in type 2 diabetes

Chadban¹,

Howell²,

Twigg³

et al. 2010

Nephrology

View full text Add to dashboard Cite

show abstract

“…Several additional analyses have also assessed cardiovascular risk associated with rosiglitazone [12][13][14][15][16]102,103]. The Integrated Clinical Trial Analyses conducted by the sponsor, GSK [102], and the meta-analysis conducted by the US FDA [103], were based on 42 randomized trials (only 28 of these being identical to those included in the Nissen and Wolski meta-analysis).…”

Section: Additional Analysesmentioning

confidence: 99%

“…Neither serious IHD events nor the clinically more relevant triple composite end point of CVD, MI or stroke, or its individual components, yielded a statistically significant increase in risk with rosiglitazone. Of note, the results of the FDA analysis using the Mantel-Haenszel approach (with continuity correction of 0.5 added) were more [12], an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) trial (which had the highest number of MI events reported) [13] and three large observational studies -one commissioned by the sponsor, the Balanced Cohort Study [14], and two conducted independently by Tricare for the Department of Defense and by WellPoint [15]. An updated meta-analysis of four trials with a follow-up of greater than 12 months revealed a statistically significant 42% increase in the risk of MI associated with rosiglitazone [16].…”

Section: Additional Analysesmentioning

confidence: 99%

“…Indeed, the all-cause mortality estimates for pioglitazone (OR: 0.92; 95% CI: 0.76-1.11) appear to be similar to those of rosiglitazone (OR: 0.90; 95% CI: 0.71-1.15) raising questions about the superior safety profile of the former. The relationship between TZD use and CHF has been demonstrated in a number of studies [12,16,[19][20][21], and TZDs are not recommended for use in individuals with class III or IV New York Heart Association (NYHA) CHF [104]. The association is felt to be the result of increased fluid retention and expansion of plasma volume by TZDs, however, the underlying mechanism for this volume expansion is not fully known [19].…”

Section: Additional Analysesmentioning

confidence: 99%

See 1 more Smart Citation